Dear Editor,
Hemophilia A (HA) is the most common genetic bleeding disorders and affects 1 in 5000 male births.1 HA patients suffer spontaneous soft-tissue and joint bleeding or life-threatening intracranial hemorrhage. The main clinical treatment for severe HA patients is life-long maintenance of protein replacement therapy, which increase the risks of infection and induce FVIII inhibitors. Gene therapy is expected to cure HA, however, the current AAV-based gene addition strategy is limited by its loading capacity, immunogenicity of capsids, and the risk of insertional mutagenesis.2 Therefore, the aim of this study is to overcome these limitations by a combination of gene editing and ex vivo strategy for HA gene therapy.
Genetically, HA is caused by mutations in F8 encoding coagulation factor VIII (FVIII), which comprises three A domains, one B domain (~44% of FVIII), and two C domains. It is reported that 15–26% of severe HA patients harbor mutations involving the sequences coding FVIII B domain (F8-B), second only to the intron 22-inversion mutation (45%). Notably, the FVIII that ultimately exerts coagulation function does not contain the B domain. In recent decades, a version of FVIII lacking most of the B domain (BDD-FVIII) was developed, and exogenous BDD-FVIII or BDD-F8 subsequently appeared to be safe and effective in preclinical studies or clinical management of HA patients.3 FVIII harbors 19 N-linked glycosylation sites within B domain. Partial B-domain-deleted FVIII, which retains several N-linked glycosylation sites, secretes more efficiently due to increased endoplasmic reticulum-to-Golgi transport.4 However, it remains unclear whether endogenous FVIII with either partial or entire F8-B deletion retains coagulation function. Recently, we discovered that reframed F8 within 54-bp deletion in F8-B could express functional FVIII, and hence hypothesized that in situ genetic manipulations of F8 to create an entire F8-B deletion might represent a therapeutic strategy for all HA patients with mutations in F8-B. Here we evaluated this strategy in HA patient-derived induced pluripotent stem cells (HA-iPSCs) and normal human iPSCs (N-iPSCs) using clustered regularly interspaced short palindromic repeats-associated protein-9 nuclease (CRISPR/Cas9) (Fig. 1a).
HA-iPSCs were previously generated from urine cells of an HA patient (c.3167del CTGA).5 To rule out re-cutting of the fused sequences (Ser743 fused to Gln1638) by CRISPR/Cas9, we retained the coding sequences for Gln744 and Asn745 to ensure the fusion of Asn745 to Pro1640 (Supplementary Fig. S1a). The dual single-guide RNAs (sgRNAs) F8-BDU-sg1 and F8-BDD-sg4 were designed with verification of the cleavage activity (Supplementary Fig. S1b). Plasmids expressing the CRISPR/Cas9 complex and sgRNAs along with the corresponding ssODN template were nucleofected into the HA-iPSC and N-iPSC lines. We achieved high targeting efficiency of 4.17% without any screening (Fig. 1b and Supplementary Fig. S1c). The stable BDD-F8 clones maintained pluripotency and a normal karyotype (Supplementary Fig. S1d–f). No off-target indels were observed (Supplementary Fig. S2). The reframed F8 transcript of the BD-iPSCs was detected (Supplementary Fig. S3a); however, almost no FVIII was detected in supernatant from iPSC culture (Supplementary Fig. S3b). Western blot revealed almost undetectable levels of lectin mannose-binding 1 (LMAN1), which reportedly mediates FVIII secretion (Supplementary Fig. S3c).
Given that ECs are the main cell type secreting FVIII, we differentiated BD-iPSCs into EPCs/ECs and evaluated FVIII expression in BD-iPSC-derived EPCs (BD-iEPCs) and ECs (BD-iECs). The differentiation efficiencies ranged from 16 to 26% (Fig. 1c). Pure iEPCs expressing CD31 and CD144 and mature ECs expressing von Willebrand factor (vWF) were obtained (Supplementary Fig. S3d). F8 transcription in BD-iECs was detected (Supplementary Fig. S3e). The secreted FVIII was 1.00 ng/106 cells and 0.52 ng/106 cells from BD21-iECs and BD25-iECs respectively, both of which were higher than that from HA-iECs (0.17 ng/106 cells) and close to that from N-iECs (0.60 ng/106 cells) (Fig. 1d). We detected LMAN1 in ECs, possibly explaining why FVIII secreted from iECs but not from iPSCs (Supplementary Fig. S3c). Importantly, immunostaining by both N-terminal and C-terminal FVIII antibody revealed restoration of FVIII expression in BD-iECs, whereas the truncated FVIII was detected in HA-iECs by a N-terminal FVIII antibody (Fig. 1e). These results demonstrated an expression and secretion of endogenous BDD-FVIII in BD-iECs.
To determine the expression efficiency of endogenous N8-FVIII, we constructed an in situ partial B-domain-deleted N8-FVIII variant harboring 271 amino acids at the N-terminus (Fig. 1f and Supplementary Fig. S4a). The iPSCs harboring the N8-FVIII variant were obtained with an efficiency of 14.58% (Supplementary Fig. S4b–d). N8-9-iPSCs and N8-46-iPSCs clones that expressed pluripotent genes, maintained a normal karyotype, and transcribed reframed N8-FVIII (Supplementary Fig. S4e–g) were selected for further experiments. Almost no FVIII was detected in culture supernatant of iPSCs (Supplementary Fig. S4h, i). Sanger sequencing revealed no indels at the putative off-target sites (Supplementary Fig. S5). N8-iPSCs were differentiated to EPCs (N8-iEPCs) and ECs (N8-iECs) (Fig. 1c and Supplementary Fig. S6a) that were characterized by angiogenesis and Dil-acetylated-low-density-lipoprotein endocytosis (Supplementary Fig. S6b, c). The reframed N8-FVIII transcripts were detected in N8-iECs (Supplementary Fig. S6d), which were eightfold higher than those in HA-iECs and threefold higher than those in BD-iECs (Fig. 1g), although well lower than that in primary liver sinusoidal endothelial cells (LSECs) with highest FVIII production capacity described previously. FVIII levels in supernatant of N8-9-iECs and N8-46-iECs were significantly higher than that in BD-iECs (Fig. 1d). Meanwhile, FVIII expression in N8-iECs was confirmed by immunostaining (Fig. 1e), and LMAN1 was detected in ECs (Supplementary Fig. S6e).
To validate the therapeutic effects of endogenous BD-FVIII and N8-FVIII, we transplanted HA-iEPCs, reframed iEPCs, and N-iEPCs into HA mice via retro-orbital vein injection. By 2 weeks post-infusion, HA mice were subjected to a tail-clip challenge and plasma FVIII activity assays. The average survival time of HA mice transplanted with BD-iEPCs and N8-iEPCs (24.62 h and 29.25 h, respectively) were significantly longer than those of untreated mice (5.73 h) (Fig. 1h, i). Notably, three of the 18 HA mice transplanted with BD-iEPCs and 3 of the 18 HA mice with N8-iEPCs were alive 48 h after tail-clip challenge (the experiment endpoint). Furthermore, we observed higher plasma FVIII activities in HA mice transplanted with BD-iEPCs and N8-iEPCs (12.79% and 10.49%, respectively) than that in HA mice (3.88%) (Fig. 1j). These results indicated that endogenous FVIII with partial or entire deletion of F8-B could exert coagulation function and systematic infusion of the reframed iEPCs could rescue FVIII deficiency in HA mice, firstly demonstrating in vitro and in vivo functionality of FVIII which is encoded by endogenous F8 with deletion of the entire B domain. Using immunostaining of anti-human vWF antibody, we identified positive cells in the livers of HA mice transplanted with iEPCs but not in mice injected with Dulbecco’s phosphate-buffered saline (DPBS) (Fig. 1k), and positive signals were observed in the lungs and spleens of iEPC-transplanted mice but not in the heart or kidney (Fig. 1l, m). Additionally, no obvious damage to the liver or kidney was observed within the 2-week observation period (Supplementary Fig. S6f–h).
In summary, we achieved an efficient targeted F8-B deletion in HA-iPSCs and the derived iECs could express functional FVIII. Transplantation with the F8-B-deleted iEPCs could restore FVIII function and rescue the bleeding phenotype in HA mice. These findings provide a proof of concept for the production of the functional FVIII from endogenous F8 with targeted B-domain deletion and preclinical validation of an autologous stem cell gene therapy for HA.
Data availability
All data relevant to this work are included in this paper and Supplementary Information.
References
Ragni, M. V. Hemophilia as a blueprint for gene therapy. Science 374, 40–41 (2021).
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target Ther. 6, 53–77 (2021).
Pasi, K. J. et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N. Engl. J. Med. 382, 29–40 (2020).
Miao, H. Z. et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 103, 3412–3419 (2004).
Hu, Z. et al. ssODN-mediated in-frame deletion with CRISPR/Cas9 restores FVIII function in hemophilia A-patient-derived iPSCs and ECs. Mol. Ther. Nucleic Acids 17, 198–209 (2019).
Acknowledgements
We thank the patient for participation in this study. This work was supported by grants from the National Natural Science Foundation of China (82101957, 81770200), the China Postdoctoral Science Foundation (2020TQ0362), the Natural Science Foundation of Hunan Province (grant number 2021JJ40806) and the National Key Research and Development Program of China (2016YFC0905102).
Author information
Authors and Affiliations
Contributions
D.L. and M.Z. designed and supervised the study and edited the manuscript; Z.H., M.Z., Z.L., Y.W., and J.Z. performed the experiments; Z.H. drafted the manuscript; M.Z. prepared the figures; Z.L., Y.W., J.Z., and L.W. assisted in manuscript preparation; and all authors read and approved the final version of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics declarations
The study was conducted in accordance with the Declaration of Helsinki, and was approved by the Ethics Committee of the School of Life Sciences, Central South University (No. 2020-2-5 and No. 2020-1-6).
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Hu, Z., Li, Z., Wu, Y. et al. Targeted B-domain deletion restores F8 function in human endothelial cells and mice. Sig Transduct Target Ther 7, 189 (2022). https://doi.org/10.1038/s41392-022-01016-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41392-022-01016-9